Abstract | BACKGROUND: METHODS: patients with advanced non-small cell lung cancer habouring ALK positive were randomly divided into crizotinib group (n=14) and chemotherapy group (n=14). Patients in the crizotinib group were receive oral treatment with crizotinib (250 mg) twice daily. Patients in the chemotherapy group were administrated docetaxel injection (75 mg/m2) every three weeks and every patient was treated at least 3 period. Then clinical efficacy was observed after 12 mo followed-up. RESULTS: Effective rate of patients in the crizotinib group was 64.29%. It was significantly higher than that of the chemotherapy group (21.43%)(P=0.026). The stable rate of patients in the crizotinib group was 85.71%. It was significantly higher than that of the chemotherapy group 40.86% (χ2=5.600, P=0.018). Median progression free survival (PFS) of the crizotinib group was 7.0 mo. It was longer than that of the chemotherapy group (4.0 mo)(P=0.002). CONCLUSIONS:
|
Authors | Jing Zhao, Kun Zhang, Liyu Zhang, Hong Wang |
Journal | Zhongguo fei ai za zhi = Chinese journal of lung cancer
(Zhongguo Fei Ai Za Zhi)
Vol. 18
Issue 10
Pg. 616-20
(Oct 20 2015)
ISSN: 1999-6187 [Electronic] China |
PMID | 26483333
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Pyrazoles
- Pyridines
- Crizotinib
- ALK protein, human
- Anaplastic Lymphoma Kinase
- Receptor Protein-Tyrosine Kinases
|
Topics |
- Adult
- Anaplastic Lymphoma Kinase
- Antineoplastic Agents
(administration & dosage, adverse effects)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, enzymology, genetics)
- Crizotinib
- Female
- Humans
- Lung Neoplasms
(drug therapy, enzymology, genetics)
- Male
- Middle Aged
- Protein Kinase Inhibitors
(administration & dosage, adverse effects)
- Pyrazoles
(administration & dosage, adverse effects)
- Pyridines
(administration & dosage, adverse effects)
- Quality of Life
- Receptor Protein-Tyrosine Kinases
(antagonists & inhibitors, genetics, metabolism)
- Treatment Outcome
- Young Adult
|